Actinic Keratoses clinical trials at UC Cancer

• Comparing Immune Responses to Topical Imiquimod

  open to eligible people ages 18-85

  The study is a basic science research study that is designed to characterize and compare the immune response in individuals who are designated as ABO blood group secretors, meaning they have a functional copy of the FUT2 gene versus those patients who are designated ABO non-secretors after application of topical imiquimod to these patients.

  at UC Davis

Last updated: March 18, 2021